RazorMetrics Achieves Surescripts® Clinical Direct Messaging Certification
AUSTIN, Texas, March 25, 2025 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment solutions, recently achieved Surescripts ® Clinical Direct Messaging certification for its medication change orders. This certification enhances RazorMetrics' ability to deliver cost-saving medication recommendations directly to prescribers' electronic health records (EHRs), ensuring timely and secure communication.
'With Surescripts certification, we are expanding our communication capabilities to help prescribers access cost-saving recommendations within their existing workflows,' said Tom Dorsett, CEO at RazorMetrics. 'By integrating with the Surescripts network, we're providing another efficient way for providers to make informed medication decisions that support both cost savings and patient care.'
Surescripts Clinical Direct Messaging provides a secure, streamlined method for transmitting medication change orders to prescribers' EHRs. This integration allows prescribers to receive actionable medication recommendations without disrupting their workflow.
'Surescripts is simplifying health intelligence sharing, enabling care providers with technologies like Clinical Direct Messaging that allows them to send and receive secure, HIPAA-compliant information as part of their existing workflow, so care providers can more efficiently manage time-sensitive communications and provide better informed, safer and less costly care to their patients,' said Matt Koehler, VP of Product Innovation for Surescripts. 'We look forward to collaborating with RazorMetrics as part of the Surescripts Network Alliance® to empower prescribers with the information they need to make better-informed medication decisions with their patients.'
RazorMetrics' certification ensures compliance with Surescripts' security protocols to ensure a seamless exchange of protected health information.
With this new capability, RazorMetrics will begin transmitting change orders electronically in March 2025, with plans to scale to over 10,000 messages per month over the next six months. This milestone underscores RazorMetrics' commitment to offering a fully integrated, multi-channel provider communication strategy, ensuring that prescribers receive cost-saving recommendations in the way that best fits their workflow.
razormetrics.com.
About RazorMetrics
RazorMetrics creates cutting-edge pharmacy cost containment solutions to quickly and easily reduce drug costs. Its proprietary technology automatically initiates cost-saving opportunities through medication switching, deprescription, deduplication, and more–all while adapting to fit client's plan, preferences, and formulary. RazorMetrics conveniently plugs into prescriber's existing workflow, improving healthcare decisions while seamlessly reducing medication costs for members and plan sponsors. Based in Austin, TX, RazorMetrics supports self-funded employers, health plans, PBMs, and organizations to bring clarity, efficiency, and more value to their pharmacy benefits. Learn more at razormetrics.com.
Media Contact
308.627.6897
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
China-ASEAN Cultural and Museum Institutions Jointly Explore "Museums and Future of Cities"
LIUZHOU, China, Aug. 18, 2025 /PRNewswire/ -- This is a report from Titled "Museum and Future of Cities," the 2025 ASEAN-Oriented Cultural Exchange and Cooperation Forum was held in Liuzhou, Guangxi, China on August 18. Co-hosted by the Bureau of International Exchange and Cooperation of the Ministry of Culture and Tourism, P.R. China and the Department of Culture and Tourism of Guangxi Zhuang Autonomous Region, the forum closely addressed the timely topic of people-to-people and cultural exchanges between China and ASEAN. Focusing on "Museum and Future of Cities," it centered on two topics for thematic discussion: "Conservation of Industrial Heritage and Innovative Urban Tourism Experiences" and "Integration of Digital Technologies and Museums for In-Depth Development." Through keynote speeches and special presentations, participants engaged in extensive and in-depth sharing and discussions from various dimensions of theoretical research and applied practice. A total of 18 prominent experts and scholars from ASEAN countries and host China — representing fields of cultural heritage and museums — contributed their insights from angles including cultural policy, heritage management, research trends, and practical experience, reaching numerous consensuses. At the forum, the Asia-Pacific Alliance of the International Council of Museums (ICOM) and the Liuzhou Industrial Museum of China signed the "Memorandum of Understanding on Cooperative Research on the Conservation of Industrial Heritage and Sustainable Development." Aimed at building an international platform to jointly study paths for the conservation, activation, and sustainable development of industrial heritage and cities, this agreement marks a solid step forward in cooperation within this field. On the occasion of the forum, key guests also attended the "Guangxi Night" 2025 Guangxi (Liuzhou) Inbound Tourism Promotion Conference. They further visited cultural and tourism venues such as Baili Liujiang River Scenic Area (Night Cruise on the Liujiang River), Liuzhou Industrial Museum, Liuzhou Bauhinia Cultural and Creative Corridor, Luosifen Industrial Park, and SAIC-GM-Wuling Automobile Base for inspection and research. Through on-site visits and hands-on experiences, they deepened their understanding of the vivid practices and diverse pathways of "Museum and Future of Cities," thereby boosting cultural exchange and tourism cooperation between China and ASEAN. View original content to download multimedia: SOURCE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
7 minutes ago
- Associated Press
RuggON Showcases AI-Powered Rugged Solutions to Boost Efficiency, Safety, and Connectivity in Logistics at TILOG LOGISTIX 2025
From AI-powered driver safety to real-time fleet diagnostics and always-on connectivity, RuggON empowers logistics operators to thrive in the most demanding warehouse, fleet and field environments. TAIPEI, Aug. 18, 2025 /PRNewswire/ -- RuggON, a subsidiary of Ubiqconn Technology and a leading provider of rugged mobile computing solutions, will showcase its latest logistics-focused innovations at TILOG LOGISTIX 2025 (Booth No. A29). Designed to address the toughest operational challenges in today's supply chain, RuggON's solutions empower warehouse, fleet, and field operators to achieve higher efficiency, safety and always-on connectivity. Key highlights include AI Safety for driver behavior analysis and blind spot detection, and Smart Monitor featuring CAN bus and SAE J1939 compatibility to deliver real-time diagnostics that minimize downtime. Reliable Connectivity through LEO satellite, 5G, 4G/LTE, and WiFi-ready capabilities ensures uninterrupted data exchange, while rugged performance is engineered to withstand shock, dust, and extreme temperatures, making it ideal for warehouse docks, delivery fleets, and challenging outdoor logistics environments. 'Logistics today demands not only speed and accuracy but also systems that can operate without fail in any environment,' said Sean Lee, VP of RuggON Business. 'By combining AI-driven analytics with our proven expertise in rugged design, we deliver solutions that help logistics operators stay productive, protect their assets, and adapt to the fast-evolving demands of global supply chains.' By integrating AI intelligence with proven durability, RuggON equips logistics operators to optimize fleet management, enable real-time tracking, and enhance inventory control, paving the way for smarter and more resilient supply chains. Visitors can experience RuggON's rugged solutions in action at TILOG LOGISTIX 2025, Booth No. A29. About RuggON RuggON Corp., a subsidiary of Ubiqconn Technology, is a leading manufacturer of rugged mobile computing solutions. Combining Ubiqconn's advanced technology to drive innovation and expand in the Mobile Industrial (IioT) market, RuggON leverages decades of expertise to improve mobile productivity in harsh environments. A committed engineering team delivers devices of exceptional value and quality that enhance user experience. The company understands the diverse demands of industries to provide tailored, efficient solutions. RuggON is dedicated to higher standards for customer satisfaction and prides itself on offering endless possibilities to meet tomorrow's needs. For more information, visit or follow us on LinkedIn. View original content to download multimedia: SOURCE RuggON Corp.
Associated Press
11 minutes ago
- Associated Press
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-derived medicinal products. This MOU formalizes and deepens a relationship that began in 2015, when GC Biopharma supported TRCS to establish a plasma fractionation facility in Thailand, and reflects the ongoing strategic collaboration between the two parties. Under the terms of the MOU, GC Biopharma and TRCS will jointly develop and operate on-site training and exchange programs for local production personnel. These programs aim to transfer GC Biopharma's advanced manufacturing technologies and expertise to support the development of local capabilities. In addition, both parties intend to continue identifying and expanding collaborative opportunities that align with their respective strengths and interests. The scope of cooperation will be gradually broadened to include potential joint projects such as the transfer of new processing technologies for plasma by-products and other strategic projects. 'This MOU is a significant step in broadening the reach of GC Biopharma's advanced technology and production standards across Asia,' said Hyoungjun Park, Vice President of GC Biopharma. 'Through our collaboration with the TRCS, we aim to achieve mutual growth while contributing to the public good.' 'Enhancing our personnel's capabilities through specialized training and direct knowledge transfer from GC Biopharma is essential to maintaining the quality, safety, and continuity of plasma-derived medicinal products production in Thailand,' said Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre, TRCS. 'This collaboration not only supports the human resource development but also represents an important step for technology transfer and playing a vital role in strengthening the country's pharmaceutical and public health security.' Meanwhile, GC Biopharma continues to expand its global plasma-derived therapeutics business. In addition to entering the U.S. immunoglobulin market in 2024, the company is actively building partnerships in Southeast Asia, where domestic fractionation capabilities remain limited. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] View original content to download multimedia: SOURCE GC Biopharma
